TY - JOUR
T1 - Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19
T2 - matched-paired analysis in the EPICOVIDEHA registry
AU - Marchesi, Francesco
AU - Salmanton-García, Jon
AU - Buquicchio, Caterina
AU - Itri, Federico
AU - Besson, Caroline
AU - Dávila-Valls, Julio
AU - Martín-Pérez, Sonia
AU - Fianchi, Luana
AU - Rahimli, Laman
AU - Tarantini, Giuseppe
AU - Grifoni, Federica Irene
AU - Sciume, Mariarita
AU - Labrador, Jorge
AU - Cordoba, Raul
AU - López-García, Alberto
AU - Fracchiolla, Nicola S.
AU - Farina, Francesca
AU - Ammatuna, Emanuele
AU - Cingolani, Antonella
AU - García-Bordallo, Daniel
AU - Gräfe, Stefanie K.
AU - Bilgin, Yavuz M.
AU - Dargenio, Michelina
AU - González-López, Tomás José
AU - Guidetti, Anna
AU - Lahmer, Tobias
AU - Lavilla-Rubira, Esperanza
AU - Méndez, Gustavo Adolfo
AU - Prezioso, Lucia
AU - Schönlein, Martin
AU - Van Doesum, Jaap
AU - Wolf, Dominik
AU - Hersby, Ditte Stampe
AU - Magyari, Ferenc
AU - Van Praet, Jens
AU - Petzer, Verena
AU - Tascini, Carlo
AU - Falces-Romero, Iker
AU - Glenthøj, Andreas
AU - Cornely, Oliver A.
AU - Pagano, Livio
N1 - Funding Information:
EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.
AB - Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.
KW - COVID-19
KW - Hematologic malignancies
KW - Passive immunization
KW - Tixagevimab/cilgavimab
U2 - 10.1186/s13045-023-01423-7
DO - 10.1186/s13045-023-01423-7
M3 - Comment/Letter to the editor
C2 - 37005697
AN - SCOPUS:85151381738
SN - 1756-8722
VL - 16
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 32
ER -